Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories

Page 2

Alzheon withdraws second IPO attempt
Aptus-backed neurodegenerative-focused company Alzheon has withdrawn its second attempt at initial public offering, less than year after cancelling its first bid.
Venturing in 2018 – the trends
Rob Lavine, News editor for Global Corporate Venturing, reviews the trends in venturing from 2018
Analysis: Lyft to go public in 2019
The first flotation of a ride hailing business, expected in early 2019, will give an exit to a range of corporate investors and will move this business model into public markets.
Moderna loads up $604m in IPO
AstraZeneca, Merck & Co and Alexion all scored exits as mRNA therapy developer Moderna floated in the largest biotech IPO of all time.
Mogu modulates US IPO
Tencent, Ping An and Bertelsmann-backed e-commerce platform Mogu has floated on the New York Stock Exchange in a $66.5m initial public offering.
Moderna adjusts IPO target to $521m
AstraZeneca, Merck and Alexion-backed Moderna Therapeutics has set its pricing range at $22 to $24 and would raise more than $521m if it floats at the top end.
Tuanche settles on $20m IPO
The Bertelsmann automotive e-commerce platform has priced its shares at the lower end of its range to raise $20m instead of its targeted $150m.
Babytree nurses $217m IPO
Alibaba-backed Babytree priced its shares at the foot of its range and will raise $217m at a valuation of $1.5bn, down from $2.2bn earlier this year.
Tongcheng-eLong books $180m flotation
The travel booking platform, backed by Ctrip, Dalian Wanda and Tencent, has priced shares at the bottom of its range and raised $180m in its initial public offering.
Vapotherm turns up final IPO size
The Kaiser Permanente-backed medical device producer upscaled its initial public offering to $64.4m after the underwriters took up the over-allotment option.

test reg